Results 161 to 170 of about 5,890 (202)

Developmental toxicity of meglumine antimoniate and transplacental transfer of antimony in the rat

Reproductive Toxicology, 2006
Meglumine antimoniate (MA), a pentavalent antimonial (SbV) drug, has been used for the treatment of leishmaniases for over half a century but there is almost no data on its safety and kinetics during pregnancy. This study was undertaken to investigate the developmental toxicity of MA as well as the transplacental transfer of antimony (Sb) in rats ...
Francisco José Roma Paumgartten
exaly   +3 more sources

Plasma antimony determination during cutaneous leishmaniasis treatment with intralesional infiltration of meglumine antimoniate [PDF]

Tropical Medicine and International Health, 2018
AbstractObjectivesTo evaluate the antimony (Sb) in plasma of patients who underwent a standardised meglumine antimoniate (MA) intralesional infiltration protocol for cutaneous leishmaniasis treatment.MethodsThe level of Sb in plasma was determined by atomic absorption spectroscopy, before and 1, 2, 4 and 6 hours after the first intralesional ...
José Eduardo Gonçalves, Gláucia Fernandes Cota   +1 more
exaly   +3 more sources

Enhanced oral delivery of antimony from meglumine antimoniate/β-cyclodextrin nanoassemblies

International Journal of Pharmaceutics, 2008
The composition comprising the highly water-soluble drug meglumine antimoniate (MA) and beta-cyclodextrin (beta-CD) was shown previously to enhance the absorption of Sb by oral route and render MA orally active in a murine model of cutaneous leishmaniasis.
Alan De Melo, Milena Salerno, Adriano M C Pimenta   +2 more
exaly   +4 more sources

Drug Hypersensitivity Syndrome Induced by Meglumine Antimoniate

The American Journal of Tropical Medicine and Hygiene, 2009
We report a case of drug hypersensitivity syndrome (drug reaction with eosinophilia and systemic symptoms [DRESS]) induced by parenteral meglumine antimoniate (Glucantime) in a 40-year-old man who traveled to Bolivia and was treated for mucocutaneous leishmaniasis.
Fakhri, Jeddi, Eric, Caumes, Marc, Thellier, Stéphane, Jauréguiberry, Dominique, Mazier, Pierre A, Buffet   +5 more
openaire   +2 more sources

Characterization of reactions of antimoniate and meglumine antimoniate with a guanine ribonucleoside at different pH

BioMetals, 2006
It has been shown previously that Sb(V) forms mono- and bis-adducts with adenine and guanine ribonucleosides, suggesting that ribonucleosides may be a target for pentavalent antimonial drugs in the treatment of leishmaniasis. In the present work, the reactions of antimoniate (KSb(OH)(6)) and meglumine antimoniate (MA) with guanosine 5'-monophosphate ...
Cláudio, dos Santos Ferreira, Adriano Monteiro, de Castro Pimenta, Cynthia, Demicheli, Frédéric, Frézard   +3 more
openaire   +2 more sources

Comparison of Injection Meglumine Antimoniate with a Combination of Injection Meglumine Antimoniate and Carbon Dioxide Fractional Ablative Laser in Treatment of Cutaneous Leshmaniasis

Pakistan Journal of Medical and Health Sciences, 2023
Aim: To see the efficacy of meglumine antimoniate alone in comparison with combination of meglumine antimoniate and CO2 ablative laser among patients with cutaneous leishmaniasis. Study design: Quasi-experimental study. Place and duration of study: Department of Dermatology, Pakistan Emirates Military Hospital, Rawalpindi from 9th July 2020 to 8th ...
Ismat Jabin, Azhar Hosain Minhas, Farrah Yousaf, Hina Syeda, Samra Irum, Shamaila Rafique, Ghazala Yasmeen   +6 more
openaire   +1 more source

Oxidative stress in mice treated with antileishmanial meglumine antimoniate

Research in Veterinary Science, 2013
In order to improve the understanding of the toxicity of pentavalent antimony (Sb(V)), we investigated the acute effects of meglumine antimoniate (MA) on the oxidative stress in heart, liver, kidney, spleen and brain tissue of mice. Levels of lipoperoxidation and protein carbonylation were measured to evaluate the oxidative status, whereas superoxide ...
D B, Bento, B, de Souza, A V, Steckert, R O, Dias, D D, Leffa, S E, Moreno, F, Petronilho, V M, de Andrade, F, Dal-Pizzol, P R, Romão   +9 more
openaire   +2 more sources

Pharmacokinetics of antimony during treatment of visceral leishmaniasis with sodium stibogluconate or meglumine antimoniate

Transactions of the Royal Society of Tropical Medicine and Hygiene, 1988
5 patients with visceral leishmaniasis were treated with sodium stibogluconate (2 patients) or meglumine antimoniate (3 patients) given intramuscularly at a dose of 10 mg antimony (Sb) per kg body weight daily for 30 d. Blood samples were obtained at intervals during treatment and blood Sb concentrations measured by anodic stripping voltametry.
J D, Chulay, L, Fleckenstein, D H, Smith
openaire   +2 more sources

Visceral leishmaniasis during pregnancy treated with meglumine antimoniate

Infection, 1995
Data on the efficacy and safety of pentavalent antimony in the treatment of visceral leishmaniasis during pregnancy are scanty. A case of visceral leishmaniasis in a 39-year-old woman in the second trimester of pregnancy is reported here. The patient was hospitalized in poor condition with high fever and pancytopenia which had lasted for 6 weeks.
UTILI, Riccardo, RAMBALDI A, TRIPODI MF, ANDREANA A.   +3 more
openaire   +3 more sources

COMPARISON OF MEGLUMINE ANTIMONIATE AND PENTAMIDINE FOR PERUVIAN CUTANEOUS LEISHMANIASIS

The American Journal of Tropical Medicine and Hygiene, 2005
Pentamidine was compared with meglumine antimoniate (Glucantime) for 80 patients with cutaneous leishmaniasis due to Leishmania braziliensis in Peru. Of the 40 patients administered Glucantime (20 mg of antimony [Sb]/kg/day intravenously for 20 days), 31 cured (78%), 6 failed (15%), of which 5 were due to relapse, and 3 were lost to follow-up (7%).
Ellen M, Andersen, Maria, Cruz-Saldarriaga, Alejandro, Llanos-Cuentas, Maria, Luz-Cjuno, Juan, Echevarria, Cesar, Miranda-Verastegui, Olga, Colina, Jonathan D, Berman   +7 more
openaire   +2 more sources